Table 4.
Distribution of the most frequently detected HR HPVs according to cytology.
| HR HPV DNA | Cytology | χ2 | p | ||||
|---|---|---|---|---|---|---|---|
| NILM | ASCUS | LSIL | HSIL | ||||
| n (%) | n (%) | n (%) | n (%) | ||||
| HPV 16 | + | 13 (44.8) | 28 (60.9) | 24 (54.5) | 40 (75.5) | 8.628 | 0.035 * |
| − | 16 (55.2) | 18 (39.1) | 20 (45.5) | 13 (24.5) | |||
| HPV 31 | + | 11 (37.9) | 16 (34.8) | 14 (31.8) | 6 (11.3) | 10.214 | 0.017 * |
| − | 18 (62.1) | 30 (65.2) | 30 (68.2) | 47 (88.7) | |||
| HPV 33 | + | 6 (20.7) | 6 (13.0) | 5 (11.4) | 7 (13.2) | 1.398 | 0.706 |
| − | 23 (79.3) | 40 (87.0) | 39 (88.6) | 46 (86.8) | |||
| HPV 51 | + | 4 (13.8) | 5 (10,9) | 8 (18.2) | 7 (13.2) | 1.045 | 0.790 |
| − | 25 (86.2) | 41 (89.1) | 36 (81.8) | 46 (86.8) | |||
| Total: | 29 (100) | 46 (100) | 44 (100) | 53 (100) | |||
* p < 0.05. NILM—negative for an intraepithelial lesion or malignancy; ASCUS—atypical squamous cells of unknown significance; LSIL—low-grade squamous intraepithelial lesions; HSIL—high-grade squamous intraepithelial lesions.